The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation

References

• Elferink MA, de Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands. Int J Colorectal Dis. 2015;30:205–212.
   PubMed Web of Science ®Google Scholar
• Hackl C, Gerken M, Loss M, et al. A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany. Int J Colorectal Dis. 2011;26:1475–1481.
   PubMed Web of Science ®Google Scholar
• Leporrier J, Maurel J, Chiche L, et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–474.
   PubMed Web of Science ®Google Scholar
• Angelsen JH, Horn A, Sorbye H, et al. Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. Br J Surg. 2017;104:580–589.
   PubMed Web of Science ®Google Scholar
• Noren A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. Eur J Cancer. 2016;53:105–114.
   PubMed Web of Science ®Google Scholar
• Tanis E, Nordlinger B, Mauer M, et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European organisation for research and treatment of cancer #40004 and #40983. Eur J Cancer. 2014;50:912–919.
   PubMed Web of Science ®Google Scholar
• Vietti Violi N, Duran R, Demartines N, et al. Local recurrence rate in patients with colorectal cancer liver metastasis after wedge resection or percutaneous radiofrequency ablation. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology. North Am Hyperthermia Group. 2018;34:1020–1028. .
   Google Scholar
• Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109:1–10.
   Google Scholar
• Solbiati L, Ahmed M, Cova L, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012;265:958–968.
   PubMed Web of Science ®Google Scholar
• Garrean S, Hering J, Saied A, et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg. 2008;195:508–520.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–A 10-year experience at a single center. Radiology. 2016;278:601–611.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Intervent Radiol. 2018;29:268–275 e1.
   PubMed Web of Science ®Google Scholar
• Gu Y, Huang Z, Gu H, et al. Does the site of the primary affect outcomes when ablating colorectal liver metastases with radiofrequency ablation? Cardiovasc Intervent Radiol. 2018;41:912–919.
   PubMed Web of Science ®Google Scholar
• Sotirchos VS, Petrovic LM, Gonen M, et al. Colorectal cancer liver metastases: biopsy of the ablation zone and margins can be used to predict oncologic outcome. Radiology. 2016;280:949–959.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249:364–374.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Garg S, Petrovic LM, et al. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol. 2012;19:4262–4269.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Del Prete V, Crucinio N, et al. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases. World J Gastroenterol. 2016;22:4211–4218.
   PubMed Web of Science ®Google Scholar
• Odisio BC, Yamashita S, Huang SY, et al. Impact of prior hepatectomy history on local tumor progression after percutaneous ablation of colorectal liver metastases. J Vasc Intervent Radiol. 2018;29:395–403.e1.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.
   PubMed Web of Science ®Google Scholar
• Vincenzi B, Cremolini C, Sartore-Bianchi A, et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget. 2015;6:31604–31612.
   PubMedGoogle Scholar
• Wood KW, Sarnecki C, Roberts TM, et al. Ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell. 1992;68:1041–1050.
   PubMed Web of Science ®Google Scholar
• Troppmair J, Bruder JT, App H, et al. Ras controls coupling of growth factor receptors and protein kinase C in the membrane to Raf-1 and B-Raf protein serine kinases in the cytosol. Oncogene. 1992;7:1867–1873.
   PubMed Web of Science ®Google Scholar
• Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17:572–578.
   PubMed Web of Science ®Google Scholar
• Varghese HJ, Davidson MT, MacDonald IC, et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res. 2002;62:887–891.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120:3965–3971.
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–626.
   PubMed Web of Science ®Google Scholar
• Margonis GA, Kim Y, Sasaki K, et al. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122:2698–2707.
   PubMed Web of Science ®Google Scholar
• Osumi H, Shinozaki E, Suenaga M, et al. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. Int J Cancer. 2016;139:803–811.
   PubMed Web of Science ®Google Scholar
• Margonis GA, Spolverato G, Kim Y, et al. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:4158–4165.
   PubMed Web of Science ®Google Scholar
• Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol. 2018;28:2727–2734.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Vakiani E, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8:66117–66127.
   PubMedGoogle Scholar
• Chen TM, Huang PT, Lin LF, et al. Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single center experience. J Gastroenterol Hepatol. 2008;23:e445–e450.
   PubMed Web of Science ®Google Scholar
• Hinshaw JL, Laeseke PF, Winter TC, 3rd, et al. Radiofrequency ablation of peripheral liver tumors: intraperitoneal 5% dextrose in water decreases postprocedural pain. Am J Roentgenol. 2006;186:S306–S310.
   PubMed Web of Science ®Google Scholar
• Liu CH, Yu CY, Chang WC, et al. Computed tomographic-guided percutaneous radiofrequency ablation with hydrodissection of hepatic malignancies in the subcapsular location: evaluation of safety and technical efficacy. J Chin Med Assoc. 2016;79:93–100.
   PubMed Web of Science ®Google Scholar
• Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol. 2013;36:166–175.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273:241–260.
   PubMed Web of Science ®Google Scholar
• Vyslouzil K, Klementa I, Stary L, et al. [Radiofrequency ablation of colorectal liver metastases]. Zentralbl Chir. 2009;134:145–148.
   PubMed Web of Science ®Google Scholar
• Weng M, Zhang Y, Zhou D, et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS One. 2012;7:e45493.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Solbiati L, Meloni F, et al. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer. 2003;97:3027–3035.
   PubMed Web of Science ®Google Scholar
• Renaud S, Romain B, Falcoz PE, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015;112:720–728.
   PubMed Web of Science ®Google Scholar
• Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121:1195–1203.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Intervent Radiol. 2011;22:755–761.
   PubMed Web of Science ®Google Scholar
• Mahnken AH, Bruners P, Tacke JA, et al. [CT-guided radiofrequency ablation of liver metastases from colorectal cancer]. Dtsch Med Wochenschr. 2009;134:976–980.
   PubMed Web of Science ®Google Scholar
• Loes IM, Immervoll H, Sorbye H, et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer. 2016;139:647–656.
   PubMed Web of Science ®Google Scholar
• Voutsina A, Tzardi M, Kalikaki A, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol. 2013;26:302–313.
   PubMed Web of Science ®Google Scholar
• Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122.
   PubMed Web of Science ®Google Scholar
• Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020–1026.
   PubMed Web of Science ®Google Scholar
• Schirripa M, Cremolini C, Loupakis F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136:83–90.
   PubMed Web of Science ®Google Scholar